Table 3.
Antimicrobial shortages by Anatomical Therapeutic Chemical classification.
| Antimicrobial Class | ATC Classification | Antimicrobial | Number of Respondents a | Total Number (%) Who Reported Antimicrobial as Unavailable | Average Duration of Shortages (days) |
|---|---|---|---|---|---|
| Penicillins | J01CF02 | Cloxacillin | 70 | 38 (54.3%) | 5 to >40 |
| J01CE08 | Benzathine Benzylpenicillin | 72 | 39 (54.2%) | 5 to >40 | |
| J01CE02 | Phenoxymethylpenicillin IV | 58 | 28 (48.3%) | 21 to >40 | |
| J01CE02 | Phenoxymethylpenicillin oral | 71 | 31 (43.7%) | 5 to >40 | |
| J01CE01 | Benzyl Penicillin | 72 | 24 (33.3%) | 5 to >40 | |
| J01CE09 | Procaine Penicillin | 55 | 14 (25.5%) | 21 to >40 | |
| J01CA01 | Ampicillin IV | 72 | 15 (20.8%) | 5 to >40 | |
| B-lactam inhibitor combinations | J01CR02 | Amoxicillin/Clavulanic Acid IV | 71 | 21 (29.6%) | 5 to >40 |
| J01CR05 | Piperacillin/Tazobactam | 61 | 16 (26.2%) | 5 to 40 | |
| Macrolides | J01FA01 | Erythromycin | 53 | 21 (39.6%) | 5 to >40 |
| J01FA10 | Azithromycin IV | 59 | 11 (18.6%) | 11 to 40 | |
| Cephalosporins | J01DD04 | Ceftriaxone | 71 | 27 (38.0%) | 5 to >40 |
| J01DE01 | Cefepime | 53 | 14 (26.4%) | 5 to >40 | |
| Aminoglycosides | J01GB03 | Gentamicin | 67 | 19 (28.4%) | 5 to >40 |
| Imidazole antifungal | D01AC01 | Clotrimazole cream | 71 | 20 (28.2%) | 5 to >40 |
| Glycopeptides | J01XA01 | Vancomycin Oral | 40 | 11 (27.5%) | >40 |
| J01XA01 | Vancomycin IV | 62 | 13 (21.0%) | 11 to 40 | |
| Synthetic nucleoside analogue antiviral | D06BB03 | Acyclovir IV | 58 | 14 (24.1%) | 5 to >40 |
| Tetraene polyene antifungal | D01AA02 | Natamycin | 43 | 8 (18.6%) | >40 |
| Polyene antifungal | J02AA01 | Amphotericin B | 72 | 13 (18.1%) | 5 to >40 |
a Total number of respondents who indicated the antimicrobial as either available or not available.